Evidence map›Paper›PMID 40668819›Full record

ArticlePLoS pathogens2025

SARS-CoV-2 encoded ORF3a interacts with YY1 to promote latent HCMV reactivation.

Sisi Xia, Xiaoping Huo, Nanfang Liu, Xinyu Liu, Tianyou Wang, Muyi Guo, Chi Zeng, Pin Wan, Jun Chen

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sisi XiaDepartment of Biological Engineering, Wuhan Polytechnic University, Wuhan, China.
Xiaoping HuoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Nanfang LiuKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Xinyu LiuKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Tianyou WangKey Laboratory of Viral Pathogenesis & Infection Prevention and Control (Jinan University), Ministry of Education, Guangzhou, China.
Muyi GuoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Chi ZengDepartment of Biological Engineering, Wuhan Polytechnic University, Wuhan, China.
Pin WanHubei Key Laboratory of Cognitive and Affective Disorders, Institute of Biomedical Sciences, School of Medicine, Jianghan University, Wuhan, China.
Jun ChenState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.ORCID 0000-0003-2447-0544

Funding

National Science Foundation of China
6 · The paper itself

Abstract

Human Cytomegalovirus (HCMV) is a commonly infected double-stranded DNA virus of the β-herpesviridae subfamily that typically establishes lifelong latency or persistent infection following primary infection. The regulation of HCMV latency and reactivation is governed by the chromatin structure at the viral major immediate early promoter (MIEP) within myeloid cells. Both cellular and viral factors play a role in regulating the reactivation of latent HCMV. Recently, it has been found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes HCMV reactivation in the clinic; however, the mechanism remains unclear. In this study, we found that SARS-CoV-2 ORF3a can activate HCMV MIEP by interacting with Yin Yang 1 (YY1), an inhibitor of MIEP. This interaction leads to YY1 ubiquitin-dependent degradation and subsequently promotes the reactivation of latent HCMV, as well as the replication and proliferation of the virus. These findings reveal the molecular mechanism underlying the interaction between SARS-CoV-2 and HCMV during co-infection, providing a new theoretical basis for future prevention and treatment strategies against the co-infection of these two viruses.

Indexed as

COVID-19CytomegalovirusCytomegalovirus InfectionsSARS-CoV-2Viral ProteinsVirus ActivationVirus LatencyYY1 Transcription FactorHEK293 CellsHumansVirus ReplicationViral ProteinsYY1 protein, humanYY1 Transcription Factor

Identifiers

PMID40668819
PMCPMC12324675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.